Stocks in the pharmaceutical (pharma) sector have had a dream run so far in 2023-24 (FY24), with the National Stock Exchange Nifty Pharma Index surging 58.2 per cent in this period against a dip of 11 per cent in 2022-23 (FY23), reveals Ace Equity data. The index has also outperformed the Nifty50, which grew by 28.7 per cent in the current financial year.
Among stocks, Orchid Pharma gave a handsome return of 210 per cent, followed by Lupin’s 157 per cent jump so far in 2023-24 (FY24).
Others like Suven Life Sciences, Venus Remedies, and Aurobindo Pharma saw 127 per